Dr. Dasilva discusses the importance of challenging longstanding monitoring practices across dermatology, encouraging clinicians to re-evaluate routine testing as new data become available. He reviews recommendations for testing done for therapies including interleukin (IL)-17 and IL-23 inhibitors, terbinafine, and isotretinoin, highlighting situations in which routine laboratory monitoring may offer limited clinical value. He examines how unnecessary testing can contribute to medical waste and patient anxiety, while emphasizing the importance of balancing patient safety with evidence-based practice. He encourages clinicians to adapt their monitoring strategies as the evidence continues to advance.
